



MODEL GENERATION TECHNICAL REPORT

Generation of mouse model : Phf6 cKO

Project code: Kos8114 / IR8144

Report finalized: 2023/10/16

1 PROJECT PROCESS & QUALITY CONTROLS

2 GENETIC STRATEGY


3 HOMOLOGOUS RECOMBINATION VECTOR CONSTRUCTION

4 ES ELECTROPORATION & SCREENING OF RECOMBINANT CLONES

5 MICROINJECTION & BREEDING

6 SEQUENCE OF THE DELIVERED ALLELE

PROJECT PROCESS & QUALITY CONTROLS



2 GENETIC STRATEGY




- Target locus structure
- mRNA(s) and protein(s)
- Genetic strategy
- PRO & CONS evaluation of the strategy


■ Phf6 mouse genomic locus – structure



Location:



Ensembl Gene ID: Phf6 ENSMUSG00000025626




■ Phf6 mRNAs and proteins



| Name | Transcript ID | Length (bp) | Protein ID | Length (aa) | Biotype | CCDS |
|----------|------------------------------------|-------------|------------------------------------|-------------|----------------------|---------------------------|
| Phf6-001 | ENSMUST00000078944 | 4350 | ENSMUSP00000077971 | 364 | Protein coding | CCDS30127 |
| Phf6-002 | ENSMUST00000154864 | 3057 | ENSMUSP00000130358 | 284 | Protein coding | - |
| Phf6-003 | ENSMUST00000101587 | 3639 | ENSMUSP00000110497 | 323 | Protein coding | - |
| Phf6-004 | ENSMUST00000179014 | 377 | No protein product | - | Processed transcript | - |
| Phf6-005 | ENSMUST00000177780 | 404 | No protein product | - | Processed transcript | - |


Phf6-001 ENSMUST0000007894



■ Approach selected: flox exons 4 and 5




Targeted allele



Exons Ensembl ID:
Ex4: ENSMUSE00001342134
Ex5: ENSMUSE00001258800

mRNA and protein obtained after Cre mediated excision (Phf6-001)



■ PROs& CONs evaluation of the strategy



Pros

- Appropriate size of the floxed fragment

Cons

- A protein of 82 aa might be expressed after Cre mediated excision if RNA decay does not occur
- Presence of repeated regions (in light) in both homology arms (green and blue arrows) might render PCR amplification and/or homologous recombination at the locus difficult

The selection cassette (FRT-Neo-FRT) will be removed by breeding male chimera with a flp deleter line which shows maternal contribution (*Birling et al., 2012*)


Highly-efficient, fluorescent, locus directed cre and FlpO deleter mice on a pure C57BL/6N genetic background.

Birling MC, Dierich A, Jacquot S, Hérault Y, Pavlovic G. *Genesis*. 2012 Jun;50(6):482-9. doi: 10.1002/dvg.20826.


3 HOMOLOGOUS RECOMBINATION - VECTOR CONSTRUCTION



Created by SnapGene




4 ES cell electroporation & Screening of recombinant clones



- Electroporation and screening process
- Long range PCR screening – strategy
- Long-Range 5' PCR screening – results
- Recombinant ES validation by Long Range PCR
- Recombinant ES clones validation by Southern Blot – internal probe
- Recombinant ES clones validation by Southern Blot – External probe
- Aneuploidy screening in ES recombinant clones

■ Electroporation and screening process




The targeting vector was electroporated in the proprietary C57BL/6NTac TB1 ES cell line.

Transfected ES clones were submitted to neomycin selection (G418) and 93 resistant ES clones were isolated. The clones were then submitted to the screening process allowing secured identification of those harbouring the expected recombination events at both ends of targeting vector.


Screening process steps:

1. Identification of candidate recombinant clones by initial 5' Long-Range PCR
2. Seven of 5' PCR positive clones are confirmed for 3' recombination event by Long-Range PCR
3. Positive clones in step2 are further validated by Southern blot analysis using internal and external probes
4. The karyotype of at least 2 validated clones is verified using Giemsa staining

Long range PCR screening – strategy





Schematic 5' and 3' PCR screening strategy




| PCR | Primer Name | Primer sequences | PCR product size |
|--------|-------------|--|------------------|
| 5' PCR | Fext | GAGATGATGTTATTACAGCCAGAAG | 6.6 kb |
| | Rneo | GCGGCCGAGAACCTGCGTGCAATC | |
| 5' PCR | Fext | GAGATGATGTTATTACAGCCAGAAG | 5.03 kb |
| | Rlox | GTTATCTGCAGGTCGACCTTAAGCT | |
| 5' PCR | Fext | GAGATGATGTTATTACAGCCAGAAG | 5 kb |
| | Rint | AATATGGCCGGCCGTGGTCAGGAGAACATTTGAAATGC | |
| 3' PCR | Fneo | AGGGGCTCGCGCCAGCCGAAGTGT | 4.2 kb |
| | Rext | AGTGCTTCATAACACTTCATGTTGC | |

Long-Range 5' PCR screening – results




PCR Fext – Rlox : 5.03 kb



B2 : Control DNA


Pcr Fext – Rint : 5 kb





Ladder pattern

Seven candidate clones out of the 7 positive clones were selected for 3' Long-Range PCR and Southern blot validation.


Recombinant ES validation by Long Range PCR




Confirmation and Validation of candidate recombinant ES clones by 5' and 3' PCRs




PCR Fext – Rneo : 6.3 kb



PCR Fext – Rlox : 4.2 kb




Ladder pattern



PCR Fneo – Rext : 4.2 kb


Seven candidate clones identified by 5' PCR screening were further analysed by 3' PCR screening. Six clones (clones #5, #11, #20, #23, #31 and 44) were confirmed.

Recombinant ES clones validation by Southern Blot – Internal probe



Schematic Southern Blot validation strategy


Digests on the scheme illustrate the position of the chosen restriction sites relative to the probe. They don't show the exact position of the restriction sites.



Digestions used to validate the 5' and 3' insertion


| Probe | | Genomic DNA digest | Targeted Allele (kb) |
|-------|-----------|--------------------|----------------------|
| Neo | 5' digest | SbfI | 11.6 |
| | 3' digest | AfIII | 9.1 |
| | | SacI | 13.1 |

Southern blot - Neo 5'



HpaI

Southern blot - Neo 3'




AfIII

SacI

Neo probe sequence


```
CTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGCTCACTGAAGCGGGAAG
GGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATG
CAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCATTTCGACCACCAAGCGAAACATCGCATCGAGCGGAGCACGTACTCGGATG
GAAGCCGGTCTTGTGCATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCCGCCAGGCTCAAGGCGCGCAT
GCCCCGACGGCGAGGATCTCGTCTGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTTCATCG
ACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCT
GACCGCTTCTCGTGCTTTACGGTATCGCCGCTCCGATTTCGACGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGGGGA
TCCGCTGTAAGTCT
```

Recombinant ES clones validation by Southern Blot – External probe



Schematic Southern Blot validation strategy

Digests on the scheme illustrate the position of the chosen restriction sites relative to the probe. They don't show the exact position of the restriction sites.




Digestions used to validate the 5' and 3' insertion

| Probe | Name | Genomic DNA digest | WT allele (kb) | Targeted Allele (kb) |
|-------------------|------------------|--------------------|----------------|----------------------|
| 3' external probe | 3' first digest | NdeI | 10.9 | 13 |
| | 3' second digest | EcoNI | 6.6 | 8.6 |

Southern blot – 3' probe

WT 5 11 20 23 31 44 wt 5 11 20 23 31 44




NdeI 10.9 / 13

EcoNI 6.6 / 8.6

3' probe sequence

```
AGACAGACAGCTCTCCAGCCCCAGTGTGGCATTATTTATATTTAGAGAATTTGGCTTTTTAG
CTCAAATTTATTTTTATTGAGTACTTTGTCAGAAACAGCTAAGATTTGTTCTGATGGGAAAT
GTGTTCTACTTTATGATGGTAATTTATGATGGGGAGTTAAAGGATTTATTTTCAGGCATTCTC
CAAGAACTATACTTCATTGGTCTCTAGGGCAAAGGACTTGATACCTGTGACAGTTTCTTTAGC
ATTTACTATCTGTAGCTCAATATTTCTGATACTAATCTGTGCATGTTAGCCTTATGCAACATGA
AGTGTTATGAAGCACT
```


■ Aneuploidy screening in ES recombinant clones



Selected recombinant ES cells clones were karyotyped by Giemsa metaphase staining. Results of aneuploidy analysis are presented in the table below.

| Clone ID | Giemsa |
|------------|-------------|
| #5 | Not done |
| #11 | Not done |
| #20 | Pass |
| #23 | Not done |
| #31 | Not done |
| #44 | Not done |

5 MICROINJECTION & BREEDING



- Microinjection
- Breeding to F1 generation

■ Microinjection



- The ES cells used in the injection experiment were originally derived from a C57BL/6N mouse strain (which have black coat colour). These cells were injected into blastocysts derived from an BALB/cN strain, which have a white coat colour. The resulting offspring are thus chimeras of two different cell types (ES cell-derived cells and host blastocyst-derived cells) and the degree of chimerism was monitored by the percentage of light and dark patches on these animals.
- Recipient blastocysts were isolated from mated BALB/cN females (Health status SPF Specific Pathogens Free).
- Recombinant ES clones #20 validated in previous project phase was injected into blastocysts to generate chimeric males. The results are presented in the table below.

| Clone ID | Number of chimeric males identified according to chimerism rate (Number of chimeric males bred to F1 generation) | | | |
|----------|---|-----------|---------|-------|
| | 5 - 40% | 45% - 55% | 60-100% | Total |
| #20 | 9 | 5 | 5 | 19 |

■ Breeding to F1 generation




- Eight highly chimeric males generated in the previous phase by blastocyst injection of the ES clones were mated with inbred C57BL/6NCrl Flp deleter females showing maternal contribution* (health status SPF – Specific Pathogen Free) to investigate whether the recombined ES cells have contributed to the germ layer.
- Germ line transmission was obtained the : 07/05/2014
- Allele nomenclature (following MGI guidelines) : **Phf6^{tm1.1lcs}**

*Highly-efficient, fluorescent, locus directed cre and FlpO deleter mice on a pure C57BL/6N genetic background.

Birling MC, Dierich A, Jacquot S, Héroult Y, Pavlovic G. Genesis. 2012 Jun;50(6):482-9. doi: 10.1002/dvg.20826.

6 SEQUENCE OF THE DELIVERED ALLELE



CTTGAATTCATAATGCAAAGGGTAAGTAAGATTAAATTAAAGCAGACAGGCATATTTTCACAGTATAATCAATTAGCTATCACAAAATATCCTCAACTCAAGAGATTCAAAGTAGTATATCTTT
CTTTTACCCTCTCCACTGGCCTACCCTCCAGTTGATTTTACCAGCTTCCCCAAAATACTGTAGGGAAGTTTTTCTCAAAGATTTTCATTTAAGTCTTTATTAATCTTCTTAAATCTTTAATAA
ATCTTCATTTAACTCTGATTTTAAGAACTCTTTGCCGATGATATTAGGACTGGTGGCAGGACATTGTGACTGGGATAGCAGTAGCATCCTTACTGTGGAAGTTTTAGAAAAAAAAAGTCTCA
TGAGATATTTTTCTAATTACTGGTATCCAGCAAGTTCTGGATTGCAAAGAGATCTAGGTTTTTATAGTGTCAGTTGTATCTAGCTCAGCTCCATGATTTATAGCATTTCAAATGTTCTCCTGA
CCACGGCCGGCCAAGCTTCTCGAGCTTAAGGTCGACCTGCAGATAACTTCGTATAATGTATGCTATACGAAGTTATTTAATTAAGTAGACCATCACACATTTATAGCATCCTACATATTTTGTG
AGTAAAATAGAAAGTACCATCAGAATAATTTTATTCAATTTTTTTCAGGAGACAAAATAAGGAAAATAACATGAATTAGACTTTTTTCTATAACCAGTTTGCTTTTCTGACAGAAATTGGAA
TGTCCTAGCCTGTTTGGGACAGTATTAGCAGAATTACATTTGAATATTGTTTTGTTGTTTTTCCCTAGATGTGTTCTCTTTGTCATTGTCTGGAGCAACCATTGGCTGTGATGTGAAAACCT
GCCACAGGACATAACCACTACCACTGTGCATTGCATGATAAAGCTCAGATCCGAGAGAAAACCTTCGCAAGGGATTACATGTAAGTGGCTCATTGCTTTGCTTTGTTTAAAGCAGCCCCGCTGT
CCTTCAGGCTTTTTCCATTTTCTCCATTCAAAGCATTTACCGTCACTATGAAGGCTTTTTTGTATATGTATGATATGTAATAGTTAAAGCAATGATTTAGGAAGTGTACACTGAGGTTTATAA
CATAATTCCAGTTTATGAATAAGGTGGACTGTGCTGCTCATTGTTTGTAAATTTGAAAATGAATTGAATTTAGTTTTATATACTTCACATTTTGTATTTTTCCCTTCAGGGTTTATTGTGCGAAAAC
ACAAGAAAACCTGCACATAACTCGGAAGGTATGTTTCATTAGCCAGTTTATGTTTCAAGAGAAAATTAGAGTAAAATATAAATGAGTAGTCCTCTACTAAGTTTTTCTTATGATAGGTCTTA
TTATTCAATATCTTTATAATTGGAGATGTTATTACATCAGTCCAATGTAAATAGTCAAAAAGAGCTAAATTTTTAAAGAAAAAAATGCCCCAGAAATCTTATGAATATACTGAAAACCTCATGTC
ATATTAGGAAGAAACTGTGGTAGAGGTGACATGTTTCTCACCGGAAGTTCCTATTCTCTAGAAAAGTATAGGAACTTCGCGGCCGGATAACTTCGTATAATGTATGCTATACGAAGTTATGG
ATCCATCGACCCCCTGCAGGCCACAGGTGGTTATTGGATTCTTGCTCCCAATAGCTATTACAGTGTGAGCCTAGGAATCCTAGTGCACCTTTGGATCAGCGTGCACCTCTGGTGAAATGTCAAC
ACCCCATCTCTGCTTTTGCTTTTCATGGTTCACCTATTCCATGGTTCAGCTCATTGCATCATGAGCTGTCATGATCCAAAATGGAAGTTTCCAAAAGAAACAAGTTTCAAATCAGTTTGAT
TATAATATATTATGCTTTATTGATGTCTTACTGTGTCCAATTTATAAGTCAGGCTTTATAATGTGTAGGCATGTGTAGGGAAAACCACTTTAGTATTATTCATGATTTTGTGTATCTACTGGGAA
TGTA AAAACAAATCCCCACTGAGAAATAAGTGGAGACATACTATGTTTTTTTTCTAGAAAAGCAAAGTTTGTAAAGTAACTAAATTTAAAATAGAAGCTTATCAAGTTATTTTATAGTTTGT
TCCACTTAAATTTATAAAACTAGTTT

LoxP

FRT

Exons 4 & 5



REPORT REDACTION & VALIDATION

Protocol finalized on 2023/10/16

Prepared by Romain LORENTZ, IE

Verified and finalized by Marie-Christine BIRLING,
PhD

CONTACT US

By email at mutagenesis@igbmc.fr

By phone at +33 (0)3 88 65 56 57

www.phenomin.fr

Genotyping protocol

Project Phf6

(PHENOMIN-ICS reference IR00004621 / G4621)

This report has been **prepared** by: David MOULAERT

This report has been **validated** by: Sylvie Jacquot, PhD
Head of Genotyping Service

The first version of this report was finalized the: 21 Sep 2016

The last update of this report was done the: 21 Sep 2016

For any question, please contact:

PHENOMIN-ICS

Email: genotypingrequest@igbmc.fr

Web site: <http://www.ics-mci.fr/>



Table of contents

| | |
|---|------------------------------------|
| 1. Genotyping protocol and data | 3 |
| 1.1. Genotyping strategy | 3 |
| 1.2. PCR protocol..... | Erreur ! Signet non défini. |
| 2. Cre and Flp genotyping method | 5 |



1. Genotyping protocol and data



This section describes the condition used at the Mouse Clinical Institute (ICS) to genotype your **Phf6** Conditional Knockout (cKO) project.

1.1. Genotyping strategy

The map below describes the position of the primers used for genotyping for each possible allele.



cKO Genotyping strategy



Sequence of primers used for genotyping:

| Position | Primers | Sequence |
|-----------------|---------|-----------------------------|
| Ef | 7822 | GGAGATGTTATTACATCAGTCCAATG |
| Er | 7821 | GCAGAGATGGGGTGTGACATTTTAC |
| Lf | 7819 | TTTTCTAATTACTGGTATCCAGCAAG |
| Lf ² | 7818 | TCTTTGCCGATGATATTAGGACTGGTG |
| Lr | 7820 | TTCTGCTAATACTGTCCCAAACAGGCT |
| Lxr | 5049 | CATACATTATACGAAGTTATCTGCAG |
| Mq1f | 1219 | CAGCTCATTCTCCCACTCATGATC |
| Mq1r | 3721 | GTAGAAGGTGGCGCGAAGGGGC |

²: for a selected position, a second primer was designed

PCR fragments expected size (bp):

| Region analyzed | Primers used | Position on the primer (see the map above) | Targeted allele (HR) | cKO allele | KO allele | WildType allele |
|--|--------------|---|----------------------|------------|-----------|-----------------|
| Presence of the distal loxP | 7819-7820 | Lf / Lr | 397 | 397 | --- | 318 |
| Excision of the selection marker | 7822-7821 | Ef / Er | 2212* | 359 | --- | 256 |
| 5' part of the selection marker | 7822-3721 | Ef / Mq1r | 361 | --- | --- | --- |
| 3' part of the selection marker | 1219-7821 | Mq1f / Er | 433 | --- | --- | --- |
| LoxP specific PCR | 7818-5049 | Lf ² / Lxr | 281 | 281 | 281 | --- |
| Excision of the floxed exon(s), i.e. knock out | 7818-7821 | Lf ² / Er | 3315* | 1462* | 432** | 1280* |

*: this PCR product will not be observed using our PCR genotyping conditions (see description below)

---: no Amplicon should be obtained



1.2. PCR protocol

This section describes the composition of the mix and cycling conditions used for genotyping.

| Reagents: | Volume: |
|--------------------------------|-------------|
| - FastStart PCR Master (Roche) | 7.5µl |
| - DNA (50ng/µl) | 1.5µl |
| - 5' primer (100 µM) | 0.06µl |
| - 3' primer (100 µM) | 0.06µl |
| - Sterile H ₂ O | up to 15 µl |

Cycling conditions:

| Temp | Time | #Cycles |
|------|------|---------|
| 95°C | 4min | 1 |
| 94°C | 30s | 34 |
| 62°C | 30s | |
| 72°C | 1min | |
| 72°C | 7min | 1 |
| 20°C | 5min | 1 |

NB: These PCR conditions have been optimized for high-throughput genotyping. Adaptation to small-scale may be required.

2. Cre and Flp genotyping method

You will find the genotyping protocol in the publication:

[Highly-efficient, fluorescent, locus directed cre and FlpO deleter mice on a pure C57BL/6N genetic background.](#)

Birling MC, Dierich A, Jacquot S, Hérault Y, Pavlovic G.
Genesis. 2012 Jun;50(6):482-9. doi: 10.1002/dvg.20826. Epub 2012 Mar 20.

